CGRP mAb Subcutaneous denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Subcutaneous CGRP Monoclonal Antibodies as Duplicate Therapy — and Why You Can Appeal

Aetna may deny a subcutaneous CGRP monoclonal antibody on the grounds that you are already authorized for — or actively using — another CGRP-pathway agent, whether injectable or oral. Because multiple approved CGRP therapies exist and their mechanisms overlap, Aetna's clinical policy treats concurrent use as therapeutic duplication. This denial is not a judgment that the drug does not work; it reflects the plan's policy that a member should be on one CGRP agent at a time.

Appeals succeed most often when the record shows that the two agents serve genuinely distinct clinical purposes, that a prior CGRP agent was discontinued before the new one was prescribed, or that your prescriber has a clinical rationale for combination use that is supported by the applicable professional guideline.

## Federal Appeal Framework

Duplicate-therapy denials are fully subject to ACA Section 2719 external review rights and, for employer-sponsored plans, ERISA Section 503 full-and-fair review. File your internal appeal within approximately 180 days of the denial. If Aetna upholds its decision, you have up to approximately four months to request independent external review. Expedited review is available when the standard timeline threatens your health.

## Concrete Appeal Steps

1. Confirm from the denial letter exactly which other CGRP agent Aetna believes duplicates this prescription. 2. Pull Aetna's published clinical policy for CGRP monoclonal antibodies and identify the duplicate-therapy criterion. 3. If the previously authorized CGRP agent has been discontinued, provide documentation of that discontinuation — date stopped, reason, prescriber note. 4. If your prescriber believes combination or sequential use is appropriate, a detailed medical-necessity letter explaining the clinical rationale is essential.

## Documentation to Gather

• Active medication list and discontinuation records: confirming which CGRP agent, if any, is currently active
• Prescriber letter: explaining the clinical distinction between the prior agent and the requested agent, or the reason for switching
• Diagnosis and severity documentation: neurologist notes confirming ongoing need for CGRP-targeted prevention
• Applicable guideline reference: reference to the American Headache Society or American Academy of Neurology position on CGRP agent selection and switching

## Criteria-Mapping Structure

Identify the specific duplicate-therapy language in Aetna's policy. For each clause, provide the chart fact that addresses it — for example, the date the prior CGRP agent was stopped and the clinical note documenting the reason. If your prescriber is intentionally transitioning between agents, the chart should reflect that transition plan with dates and rationale.